MA28607B1 - AMINOPYRIDINE DERIVATIVES USEFUL AS SELECTIVE DOPAMINE D3 AGONISTS - Google Patents
AMINOPYRIDINE DERIVATIVES USEFUL AS SELECTIVE DOPAMINE D3 AGONISTSInfo
- Publication number
- MA28607B1 MA28607B1 MA29488A MA29488A MA28607B1 MA 28607 B1 MA28607 B1 MA 28607B1 MA 29488 A MA29488 A MA 29488A MA 29488 A MA29488 A MA 29488A MA 28607 B1 MA28607 B1 MA 28607B1
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- derivatives useful
- selective dopamine
- aminopyridine derivatives
- aminopyridine
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 239000000556 agonist Substances 0.000 title 1
- 150000003927 aminopyridines Chemical class 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28607B1 true MA28607B1 (en) | 2007-05-02 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29488A MA28607B1 (en) | 2004-05-27 | 2006-11-27 | AMINOPYRIDINE DERIVATIVES USEFUL AS SELECTIVE DOPAMINE D3 AGONISTS |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (en) |
| JP (1) | JP4198183B2 (en) |
| AP (1) | AP2006003824A0 (en) |
| AR (1) | AR049548A1 (en) |
| AU (1) | AU2005247699A1 (en) |
| BR (1) | BRPI0511571A (en) |
| CA (1) | CA2567935C (en) |
| EA (1) | EA200601982A1 (en) |
| EC (1) | ECSP067029A (en) |
| GT (1) | GT200500125A (en) |
| IL (1) | IL179314A0 (en) |
| MA (1) | MA28607B1 (en) |
| MX (1) | MXPA06013786A (en) |
| NL (1) | NL1029139C2 (en) |
| NO (1) | NO20065326L (en) |
| PA (1) | PA8635101A1 (en) |
| PE (1) | PE20060366A1 (en) |
| SV (1) | SV2005002129A (en) |
| TW (1) | TW200609216A (en) |
| UY (1) | UY28925A1 (en) |
| WO (1) | WO2005115985A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| EA201101186A1 (en) | 2009-02-13 | 2012-04-30 | Байер Фарма Акциенгезельшафт | CONDENSED PYRIMIDINES |
| EP2558437B1 (en) * | 2010-04-12 | 2015-08-05 | Supernus Pharmaceuticals, Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| WO2013003769A2 (en) | 2011-06-30 | 2013-01-03 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and, methods |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| MX388518B (en) | 2016-07-20 | 2025-03-19 | Novartis Ag | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS. |
| WO2019110703A1 (en) * | 2017-12-08 | 2019-06-13 | Boehringer Ingelheim International Gmbh | Imidazopyridine derivatives and the use thereof as medicament |
| CA3136151A1 (en) * | 2019-04-12 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| JP7717065B2 (en) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| OA13014A (en) * | 2002-12-10 | 2006-11-10 | Pfizer | Morpholine derivatives for use as dopamine agonists in the treatment of i.a sexual dysfunction. |
-
2005
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/en not_active Application Discontinuation
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/en not_active Application Discontinuation
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/en unknown
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/en not_active Expired - Fee Related
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en not_active Ceased
- 2005-05-17 EA EA200601982A patent/EA200601982A1/en unknown
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-24 GT GT200500125A patent/GT200500125A/en unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/en not_active Application Discontinuation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/en unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/en not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/en unknown
- 2005-05-26 TW TW094117274A patent/TW200609216A/en unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/en not_active Application Discontinuation
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/en not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/en unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/en unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL1029139A1 (en) | 2005-11-30 |
| SV2005002129A (en) | 2005-12-13 |
| MXPA06013786A (en) | 2007-01-25 |
| NL1029139C2 (en) | 2006-06-19 |
| BRPI0511571A (en) | 2008-01-02 |
| CA2567935C (en) | 2009-10-27 |
| TW200609216A (en) | 2006-03-16 |
| UY28925A1 (en) | 2005-12-30 |
| ECSP067029A (en) | 2006-12-29 |
| PA8635101A1 (en) | 2006-05-16 |
| EP1758862A1 (en) | 2007-03-07 |
| NO20065326L (en) | 2006-12-19 |
| AR049548A1 (en) | 2006-08-16 |
| IL179314A0 (en) | 2007-03-08 |
| JP2008500331A (en) | 2008-01-10 |
| EA200601982A1 (en) | 2007-04-27 |
| GT200500125A (en) | 2006-01-10 |
| PE20060366A1 (en) | 2006-05-15 |
| AU2005247699A1 (en) | 2005-12-08 |
| WO2005115985A1 (en) | 2005-12-08 |
| AP2006003824A0 (en) | 2006-12-31 |
| JP4198183B2 (en) | 2008-12-17 |
| CA2567935A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1900034I1 (en) | 6,7-unsaturated-7-carbamoyl-substituted morphinan derivatives | |
| EP1973405A4 (en) | HYDROXYALKYMARYLAMIDE DERIVATIVES | |
| IL192053A0 (en) | 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors | |
| IL184901A0 (en) | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors | |
| DK1868999T3 (en) | Pyridine-3-carboxamide derivatives as reverse CB1 agonists | |
| PL2094263T3 (en) | 2-adamantyl-butyramide derivatives as selective 11 beta-hsd1 inhibitors | |
| DOP2007000080A (en) | PIRIDIN [3,4-B] PIRAZINONAS | |
| IL175139A0 (en) | Phenyl derivatives as ppar agonists | |
| DK1735304T3 (en) | Quinolinone carboxamide compounds as 5-HT 4 receptor agonists | |
| IL189679A0 (en) | Imidazole derivatives functionally selective alpha2c adrenoreceptor agonists | |
| IL186150A0 (en) | Novel thiophene derivatives as sphingosine-1-1phosphate-1 receptor agonists | |
| ATE481383T1 (en) | 3-AZA-BICYCLOÄ3.1.0ÜHEXANE DERIVATIVES | |
| ZA200709086B (en) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
| PL376920A1 (en) | Substituted 4-alkoxyoxazol derivatives as ppar agonists | |
| ITUD20060182A1 (en) | "DRILLING METHOD" | |
| ATE384697T1 (en) | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | |
| IL198462A0 (en) | Diazepane-acetamide derivatives as selective 11??-hsd1 inhibitors | |
| PL378342A1 (en) | 2-piperidone derivatives as prostaglandin agonists | |
| AP2006003705A0 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| PL1912647T3 (en) | Quinoline derivatives as antibacterical agents | |
| EP1746141A4 (en) | COMPOSITION FOR THICKENING | |
| EP1951231A4 (en) | CAMPTOTHECIN DERIVATIVES USEFUL AS CHEMORADIOSENSITIVE AGENTS | |
| SI1924561T1 (en) | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzosdcazepines as 5-ht2c receptor agonists | |
| MA28686B1 (en) | PYRROLOPYRIDINE DERIVATIVES | |
| ZA200706672B (en) | 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors |